How were Brickell Biotech's earnings last quarter?

Brickell Biotech, Inc. (NASDAQ:BBI) released its quarterly earnings results on Thursday, August, 11th. The company reported ($0.01) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.48) by $1.47. Brickell Biotech had a negative net margin of 643.48% and a negative trailing twelve-month return on equity of 156.10%. During the same period in the prior year, the business posted ($7.21) EPS.

When did Brickell Biotech's stock split?

Brickell Biotech shares reverse split on Tuesday, July 5th 2022. The 1-45 reverse split was announced on Tuesday, July 5th 2022. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, July 5th 2022. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split.

What other stocks do shareholders of Brickell Biotech own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Brickell Biotech investors own include Sorrento Therapeutics (SRNE) , VBI Vaccines (vbiv) , Jaguar Health (JAGX) , Miragen Therapeutics (MGEN) , Acasti Pharma (ACST) , Allena Pharmaceuticals (ALNA) , Aileron Therapeutics (ALRN) , Amarin (AMRN) , Fortress Biotech (FBIO) and iBio (IBIO) .

NASDAQ:BBI

Brickell Biotech (BBI) Stock Price, News & Analysis

→ Biden’s $374B Giveaway Into This Sector (From DTI) (Ad)

Free BBI Stock Alerts

Notice: This company has been marked as potentially delisted and may not be actively trading.

Compare

Today's Range: N/A
50-Day Range: $0.77
▼
$0.93
52-Week Range: N/A

Volume: 31,300 shs
Average Volume: 206,730 shs
Market Capitalization: $6.75 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis

Get Brickell Biotech alerts:

Ad DTI

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

Click here for the full story

About Brickell Biotech Stock (NASDAQ:BBI)

Brickell Biotech, Inc., a clinical-stage pharmaceutical company, engages in the development of various prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases in the United States. The company develops sofpironium bromide, which has completed Phase III clinical trials for the treatment of primary axillary hyperhidrosis; BBI-02, an oral DYRK1A inhibitor for the treatment of autoimmune and inflammatory diseases; and BBI-10, a covalent stimulator of interferon genes inhibitor for the potential treatment of autoinflammatory and rare genetic diseases, as well as next-generation kinase inhibitors. It has license and collaboration agreements with Carna Biosciences, Inc., Voronoi Inc., Bodor Laboratories, Inc. and Dr. Nicholas S. Bodor, and AnGes, Inc. The company was founded in 2009 and is headquartered in Boulder, Colorado.

Ad DTI

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

Click here for the full story

BBI Stock News Headlines

October 19, 2023 | bizjournals.com

Brickell hotel sold by royal family member for $55M

August 27, 2023 | dailymail.co.uk

Paul Simon and Edie Brickell's daughter speaks out following parents' arrest

April 19, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

April 25, 2023 | bizjournals.com

Seattle Biotech News

April 10, 2023 | marketwatch.com

Nuclear Receptor ROR-Gamma Market Size by 2030

March 29, 2023 | travel.usnews.com

Brickell City Centre

March 24, 2023 | bizjournals.com

Biotech News

March 18, 2023 | techcrunch.com

5 strategies for biotech startups to outlast a market downturn

April 19, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

March 14, 2023 | marketwatch.com

Nuclear Receptor ROR-Gamma Market Application, Product, Sales and Forecast 2023-2028

February 27, 2023 | finance.yahoo.com

What Sunzen Biotech Berhad's (KLSE:SUNZEN) P/E Is Not Telling You

February 27, 2023 | techcrunch.com

Biotech proved a surprisingly bright spot in 2022’s startup correction

February 21, 2023 | msn.com

Paul Simon Was 50 When He Married a 26-Year-Old Edie Brickell

February 19, 2023 | cnbc.com

This biotech hedge fund has elite clients like Yale’s endowment, Tisch. Here are its top bets

February 10, 2023 | benzinga.com

Best Biotech Penny Stocks

January 13, 2023 | markets.businessinsider.com

VERO Biotech Raises $30 Million to Accelerate Commercialization of Its Innovative Tankless Inhaled Nitric Oxide Delivery System

January 9, 2023 | cbsnews.com

USDA approves vaccine for honeybees, biotech company says

January 4, 2023 | marketwatch.com

Bioreactors and Fermenters Market 2023 Expected to Witness the Highest Revenue Growth Over Forecast to 2028

December 28, 2022 | forbes.com

Brickell Biotech

December 18, 2022 | marketwatch.com

Nuclear Receptor ROR-Gamma Market : Industry Analysis 2023 To 2028 based on Sales, Revenue, Size and Share

December 5, 2022 | nz.finance.yahoo.com

Atopic Dermatitis Pipeline Appears Robust With 90+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

September 13, 2022 | finance.yahoo.com

Fresh Tracks Therapeutics Initiates Multiple Ascending Dose Portion of Phase 1 Study of DYRK1A Inhibitor FRTX-02

September 7, 2022 | finance.yahoo.com

Brickell Biotech Announces Corporate Rebranding to Fresh Tracks Therapeutics

August 11, 2022 | seekingalpha.com

Brickell Biotech, Inc. (BBI) CEO Robert Brown on Q2 2022 Results - Earnings Call Transcript

August 2, 2022 | benzinga.com

Brickell Biotech to Report Second Quarter 2022 Financial Results and Provide a Corporate Update on August 11, 2022

July 20, 2022 | finance.yahoo.com

Brickell Biotech Regains Compliance with Nasdaq Minimum Bid Price Requirement

July 6, 2022 | finance.yahoo.com

Brickell Biotech to Participate at William Blair Biotech Focus Conference 2022

See More Headlines

Receive BBI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Brickell Biotech and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 8/11/2022
Today: 4/19/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Biological Products, Except Diagnostic
Sub-Industry: N/A
Current Symbol: NASDAQ:BBI
CUSIP: N/A
CIK: 819050
Web: www.brickellbio.com
Phone: (720) 505-4755
Fax: 858-646-1150
Employees: 16
Year Founded: 2009

Profitability

EPS (Most Recent Fiscal Year): ($13.52)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-39,470,000.00
Net Margins: -643.48%
Pretax Margin: -643.48%
Return on Equity: -156.10%
Return on Assets: -128.23%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 6.36
Quick Ratio: 6.36

Sales & Book Value

Annual Sales: $4.64 million
Price / Sales: 0.00
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $9.75 per share
Price / Book: N/A

Miscellaneous

Outstanding Shares: 2,874,000
Free Float: 2,744,000
Market Cap: $6.75 million
Optionable: Not Optionable
Beta: 0.02

Social Links

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Key Executives

Mr. Reginald L. Hardy M.B.A. (Age 64)
R.Ph., Co-Founder & Chairman
Comp: $76.83k
Attorney Robert Busard Brown (Age 60)
CEO & Director
Comp: $816.73k
Mr. Andrew D. Sklawer (Age 38)
Co-Founder, Pres, COO & Sec.
Comp: $559.58k
Mr. Deepak Chadha M.B.A. (Age 52)
M.S., MBA, MS, RAC, Chief R&D Officer
Comp: $543.59k
Mr. Albert Nicholas Marchio II (Age 70)
CFO and Principal Accounting & Financial Officer
Mr. David R. Mcavoy J.D. (Age 59)
Gen. Counsel & Chief Compliance Officer
Mr. Gary S. Walker (Age 62)
Chief Marketing Officer
Aron Aizenstat M.B.A.
P.M.P., VP of Corp. Devel. & Operations
Ms. Sue Fattor
Head of Human Resource
Ms. Nancy Seretta
VP & Head of Clinical Operations

Key Competitors

View All Competitors

BBI Stock Analysis - Frequently Asked Questions

How were Brickell Biotech's earnings last quarter?: Brickell Biotech, Inc. (NASDAQ:BBI) released its quarterly earnings results on Thursday, August, 11th. The company reported ($0.01) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.48) by $1.47. Brickell Biotech had a negative net margin of 643.48% and a negative trailing twelve-month return on equity of 156.10%. During the same period in the prior year, the business posted ($7.21) EPS.
When did Brickell Biotech's stock split?: Brickell Biotech shares reverse split on Tuesday, July 5th 2022. The 1-45 reverse split was announced on Tuesday, July 5th 2022. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, July 5th 2022. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split.
What other stocks do shareholders of Brickell Biotech own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Brickell Biotech investors own include Sorrento Therapeutics (SRNE), VBI Vaccines (vbiv), Jaguar Health (JAGX), Miragen Therapeutics (MGEN), Acasti Pharma (ACST), Allena Pharmaceuticals (ALNA), Aileron Therapeutics (ALRN), Amarin (AMRN), Fortress Biotech (FBIO) and iBio (IBIO).

This page (NASDAQ:BBI) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Brickell Biotech (BBI) Stock Price, News & Analysis

About Brickell Biotech Stock (NASDAQ:BBI)

BBI Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Social Links

Key Executives

Key Competitors

BBI Stock Analysis - Frequently Asked Questions

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info